TX-MAVENIR
16.4.2024 13:01:29 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that the Mavenir Digital Enablement (MDE) is now available on Amazon Web Services (AWS) Marketplace.
Mavenir’s Digital Enablement (MDE) Business Support System (BSS) stack with composable architecture allows Communication Service Providers (CSPs) to implement innovative strategies and new selling models quickly, cost-effectively and with minimal risk, with the ability to test models iteratively and speed time-to-market without increasing capital and resource costs. MDE’s comprehensive set of modules already run on AWS – for reduced application-to-infrastructure test times – and span customer management, product catalog, order management, CRM, billing, converged charging, API monetization and network slice charging. With low-code/no-code visual builders and templated solutions-in-a-box, MDE is now available as a one-stop destination and digital marketplace for CSPs looking to implement new or complex models simply and agilely.
MDE offers a low-risk route to introducing profitable new business models such as split or sponsored billing, new package product offerings incorporating third-party solutions, automation for inter-partner manual tasks such as catalog mapping, and notifications mapping for service delivery to improve operational efficiency and the customer experience.
Mavenir’s Digital BSS has achieved platinum certification from TM Forum, with open APIs ensuring seamless integration with existing or new third-party systems and eliminating the need for resource-intensive system integration effort.
Sandeep Singh, Senior Vice President and General Manager for Mavenir’s Digital Business Enablement commented: “Mavenir’s Digital BSS is a transformative solution for service providers looking to stay ahead of the competition and launch innovative offerings in a fast time-to-market. Our arrival on AWS Marketplace is a strategic acceleration of our mission to drive sustainable global network automation and monetization, empowering the world’s operators to roll out advanced digital experiences at scale.”
He added: “By facilitating end-to-end digitization of customer interactions and streamlining collaboration with third-party partners – all within a stable and agile architecture – MDE Digital BSS provides service providers with a complete innovation framework to create seamless, personalized network service experiences for customers, and realize the gains with flexible monetization capabilities.”
John Abraham, Principal Analyst, Appledore Research noted: “One of the main innovation barriers for CSPs is the inflexibility of incumbent legacy BSS ecosystems, which require substantial investment in time, cost, and operational resources to enable new revenue models and service capabilities. Simplifying the path to the timely introduction of new business models and innovative best practices, as Mavenir is enabling with its MDE solution, provides CSPs with a distinct advantage in time to market and TCO.”
The MDE platform not only enables greenfield service providers to bring new services to market rapidly but also empowers brownfield service providers to modernize their legacy stack, accelerate digital transformation, and provides a viable path to migrate to 5G while co-existing with existing technologies (2G/3G/4G). MDE brings marketplace capabilities to service providers to cross sell 3rd Party Partner-led product and services integrated with CSPs and Mobile Virtual Network Operators (MVNOs) worldwide. The platform uses advanced AI-ML engines to derive intelligence from customer and network data, which is then used to recommend new products based on historical behavior, and also delivers categorization capabilities that enable service providers to fully capitalize on their rich datasets – bringing new revenues and boosting customer stickiness.
Notes to editors:
- More information about Mavenir’s Digital BSS:
https://www.mavenir.com/portfolio/mavapps/mavenir-digital-enablement-bss/
- Mavenir’s listing on AWS Marketplace:
https://aws.amazon.com/marketplace/pp/prodview-ylbqlsfj3bmay
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416395684/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom